Expert data, transparent methodology and clinical parameters you can rely on.
We give doctors transparent expert data, validated methodologies and clinical parameters based on the same laboratory process in which the test is actually performed.
Analytical parameters of the NIFTY test
NIFTY achieves high sensitivity and specificity in screening for the most common fetal aneuploidies.
-
Trisomy 21
(Down syndrome)- sensitivity 99.17%
- specificity 99.95%
-
Trisomy 18
(Edwards syndrome)- sensitivity 98.24%
- specificity 99.95%
-
Trisomy 13
(Patau syndrome)- sensitivity 100%
- specificity 99.96%
-
Other
parameters- false-positive rate: 0.1%
- low rate of inconclusive results (no-call rate)
The parameters are based on a validation study on more than 147,000 pregnancies.
Clinical experience with the NIFTY® test
More than 20 million samples have been processed with the NIFTY® test worldwide (according to current BGI data). In August 2026, BGI Genomics announced that NIFTY® had received the CE-IVDR certificate. It is a proven service with extensive clinical experience that you can rely on. The laboratory's internal data show the following values for the NIFTY® test:
- 0.069% inconclusive results
- 0.1% false-positive rate for trisomies 21, 18 and 13
- 2.8% need for a repeat blood draw
Validation studies
The NIFTY® test has undergone extensive external validation. The results of selected studies are shown below; the full list of publications can be found in the Scientific literature section.
-
Non-invasive prenatal testing for trisomies 21, 18 and 13 – clinical experience from 146,958 pregnancies
Zhang H., … Wang W. Ultrasound in Obstetrics & Gynecology, 2015; 45(5): 530–538. One of the largest published studies of the clinical performance of NIPT. Source: DOI 10.1002/uog.14792 · PubMed 25598039
Trisomy True positives (TP) False positives (FP) Sensitivity Specificity Negative predictive value (NPV) T21 720 61 99.17% 99.95% 99.99% T18 167 51 98.24% 99.95% 100% T13 22 45 100% 99.96% 100% Total 909 157 99.02% 99.86% 99.99% The pregnancy outcome was known in 112,669 cases. The samples were tested between January 2012 and August 2013.
-
Non-invasive prenatal testing for fetal chromosomal abnormalities: review of 1,982 consecutive cases in a single centre
Lau T. K. et al. Ultrasound in Obstetrics & Gynecology, 2014; 43(3): 254–264. Low-coverage whole-genome sequencing of maternal plasma DNA. Source: DOI 10.1002/uog.13277 · PubMed 24339153
Trisomy 21 Trisomy 18 Trisomy 13 High risk (positive result) 23 4 2 Confirmed by karyotyping 23 4 2 Sensitivity 100% (23/23) 100% (4/4) 100% (2/2) Specificity 100% (1,959/1,959) 100% (1,978/1,978) 100% (1,980/1,980) False-positive rate 0% 0% 0% False-negative rate 0% 0% 0% 1,982 samples were tested. For negative results, the pregnancy outcome was verified in 1,645 cases.
-
Large-scale clinical validation of the NIFTY® test for trisomies 21 and 18 in 11,105 pregnant women
Dan S. et al. Prenatal Diagnosis, 2012; 32(13): 1225–1232. Multicentre study in 49 medical centres, pregnant women with mixed risk factors. Source: DOI 10.1002/pd.4002 · PubMed 23138752
Trisomy 21 Trisomy 18 Positive NIFTY® result 143 47 Verified by karyotyping * 140 42 Confirmed by karyotype 139 41 False positives 1 1 False negatives 0 0 Sensitivity 100% 100% Specificity 99.97% 99.97% False-positive rate 0.03% 0.03% * Karyotyping was performed in 182 women with a positive and 2,818 women with a negative test result. Three pregnancies with trisomy 21 and five with trisomy 18 were terminated without karyotyping; 8,097 women did not undergo invasive testing.
-
Double-blind validation study of the NIFTY® test
Source: BGI internal validation data – double-blind validation study, 3,464 samples.
Trisomy 21 Trisomy 18 Trisomy 13 Positive NIFTY® result 189 64 10 Positive karyotype 188 63 10 False positives 1 * 1 * 0 False negatives 0 0 0 Sensitivity 100% 100% 100% Specificity 99.97% 99.97% 100% False-positive rate 0.03% 0.029% 0% False-negative rate 0% 0% 0% Positive predictive value (PPV) 99.49% 98.44% 100% * Caused by insufficient sequencing depth.
-
Positive predictive value of NIFTY® PRO for microdeletion syndromes
BGI internal data: review and follow-up of positive cases from 210,217 tests (January 2019 – March 2021).
Syndrome Incidence Positive predictive value (PPV) 22q11.2 deletion syndrome (DiGeorge syndrome) 1/4,000 – 1/10,000 80.6% Prader-Willi / Angelman syndrome PWS 1/10,000 – 1/30,000, AS 1/12,000 – 1/20,000 27.8% Cri-du-chat syndrome 1/15,000 – 1/50,000 21.4% 1p36 deletion syndrome 1/5,000 – 1/10,000 10.0% 18q deletion syndrome 1/10,000 66.7% 18p deletion syndrome 1/50,000 50.0% Wolf-Hirschhorn syndrome 1/20,000 – 1/50,000 60.0% 9p deletion syndrome 1/50,000 75.0% Smith-Magenis syndrome 1/15,000 – 1/25,000 66.7% PPV shows what share of positive test results was confirmed. For rare syndromes it is naturally lower than for trisomies, which is why a positive result always requires diagnostic confirmation.
NIFTY is a screening test, not a diagnostic test. The values shown come from published clinical studies and BGI internal data. A sensitivity of 100% in smaller studies means that all cases that occurred in the given study were detected. For rare microdeletion syndromes, the positive predictive value (PPV) is naturally lower than for trisomies, which is why a positive result always requires confirmation by invasive diagnostic testing and a consultation with a doctor.
Testing methodology
-
Next-generation sequencing (NGS)
NIFTY uses massively parallel sequencing (MPS) to analyse cell-free fetal DNA from the mother's blood. It is a clinically proven methodology and one of the most widely used approaches in non-invasive prenatal genetic testing.
-
Whole-genome sequencing
The analysis is performed at whole-genome level, which allows a comprehensive evaluation of the genetic information and high analytical accuracy.
-
Bioinformatic analysis
Samples are evaluated with validated bioinformatic algorithms and quality control mechanisms. The process includes multi-step data checks that support the accuracy and reliability of the results.
Expanded screening for single-gene disorders - NIFTY® MONO
In addition to screening for chromosomal abnormalities, NIFTY also offers expanded genetic screening focused on single-gene disorders
and carrier status of genetic conditions.
-
NIFTY® MONO AD
Screening of the fetus for 218 selected autosomal dominant single-gene disorders associated with 155 genes.
Particularly suitable:
- after a pathological or inconclusive ultrasound finding,
- when a single-gene disorder is suspected,
- when the father is older,
- on the recommendation of a clinical geneticist.
Methodological advantages
Complete gene coverage
- The technology used covers the entire coding region of the target genes, including ±30 bp.
Advanced variant detection
- The test can identify known pathogenic variants, rare variants and previously unreported mutations.
UMI technology
- Analysis of unique molecular identifiers (UMI) helps reduce the risk of PCR errors, sequencing artefacts and false-positive results.
-
NIFTY® MONO AR
Screening of the mother's carrier status for 172 selected inherited conditions associated with 164 genes.
Particularly suitable:
- with a positive family history,
- when carrier status of a genetic condition is suspected,
- after a pathological ultrasound finding,
- on the recommendation of a clinical geneticist.
Whether the test is appropriate is decided by the doctor based on the clinical findings, family history and genetic indication.
Important notice
- A low-risk result does not rule out all genetic abnormalities of the fetus.
- After a high-risk result, genetic counselling and confirmation of the finding by a diagnostic method are recommended.
For doctors – all chapters

